Category Archives: – Generics

Federal Court of Appeals Rules that FDA Overstepped by Restricting Ivermectin Use

September 2, 2023- by Steven E. Greer, MD

Posted in - Generics, - Pharma, CDC, Congress, FDA | Leave a comment

Ivermectin works as an antiviral against SARS-CoV-2 (COVID-19)

Update September 4, 2022- A new peer-reviewed study found that regular use of ivermectin reduced the risk of dying from COVID-19 by 92%.

Posted in - Biotech, - Generics, - Pharma, FDA, Infectious disease | Leave a comment

Ivermectin works against COVID in double blind, randomized, controlled trial

May 2, 2023- by Steven E. Greer, MD A new medical meeting poster shows the results of a double blind, randomized, controlled trial of ivermectin as a therapy for COVID. The drug works very well.

Posted in - Biotech, - Generics, - Pharma, Congress, Emergency medicine, FDA, Infectious disease, Internal Medicine | Leave a comment

Steven E. Greer, MD on OANN discussing virus therapies

April 16, 2020

Posted in - Biotech, - Generics, - Opinion, - Pharma, CDC, CMS, Congress, Emergency medicine, FDA, Geriatrics, Infectious disease, Internal Medicine, NIH, Pediatrics, Primary care medicine, Pulmonology, VA | Leave a comment

Joe Piscopo interviews Steven E. Greer, MD: 5-22-2020

May 22, 2020

Posted in - Biotech, - Generics, - Opinion, - Pharma, - Policy, Emergency medicine, Infectious disease, Pulmonology | Leave a comment

The FDA pathway for biosimilar drug approvals

March 26, 2015- Interviewed by Steven E. Greer,

Posted in - Biotech, - Generics, FDA | Leave a comment

How to beat the virus with early treatment

July 22, 2021- by Steven E. Greer, MD I woke up yesterday with a slight malaise and I sneezed once. I knew I had come down with a virus

Posted in - Biotech, - Generics, - Opinion, - Pharma, - Policy, Duke, Emergency medicine, Geriatrics, Infectious disease, Internal Medicine, Pediatrics, Primary care medicine, Pulmonology | Leave a comment

India, Mexico, and El Salvador distribute ivermectin to citizens in free COVID kits

January 20, 2022- by Steven E. Greer, MD As all hospitals in the U.S. refuse to administer lifesaving early treatments for the SARS-CoV-2 coronavirus,

Posted in - Biotech, - Generics, - Medical Devices, - Pharma, - Policy, Infectious disease, Internal Medicine | Leave a comment

Sen. Ron Johnson on the need for early treatment of the Wuhan coronavirus

December 13, 2020- by Steven E. Greer, MD This is straight from my book, Tony’s Virus, chapters 8 and chapter 10.

Posted in - Biotech, - Generics, - Opinion, - Pharma, - Policy, CDC, CMS, Congress, FDA, NIH | Leave a comment

The Year in Review: 2018

December 29, 2018- by Steven E. Greer, MD The biggest stories this year related

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy, - Reviews, books, devices, - The Weekly Summary | Leave a comment

The super shady methods of pricing generic drugs in America: case study- Sildenafil

May 15, 2016- by Steven E. Greer, MD The last I read, Teva and Mylan were not supposed to launch their approved generic of Viagra (sildenafil)

Posted in - Generics, - Opinion, - Pharma, CMS, Congress, FDA | Leave a comment

This could be the best interview ever aired on Fox Business

August 15, 2017- by Steven E. Greer, MD Martin Shkreli was on Fox Business today, and the set seemed familiar. Ironically, I was in this same

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy | Leave a comment

The Biggest Healthcare Stories of 2016

December 26, 2016- by Steven E. Greer, MD for The Healthcare Channel Policy changes dominated the 2016 year in healthcare news. There were few important new drug

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy, - The Weekly Summary, CMS, FDA | Leave a comment

The Biggest stories of 2015

December 31, 2015- by Steven E. Nike Roshe Run Femme Greer, MD 2015 was the year of ISIS. The radical jihadist group started the year with an attack in France,

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy, - Reviews, books, devices, - The Weekly Summary | Leave a comment

Actavis 1000% drug price hike: a case for healthcare reform

Update September 21, 2015- The Healthcare Channel was the first to report in 2009 on the business strategy of acquiring cheap generic drugs, cornering the market, then raising

Posted in - Biotech, - Generics, - Opinion, - Policy, CMS, Congress, FDA, Infectious disease | Leave a comment